Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYMPHONY-1
2024-510690-16-00Phase 3Authorised
- Sponsor
- Epizyme, Inc.
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial in follicular lymphoma (FL) comparing tazemetostat + lenalidomide + rituximab with placebo + lenalidomide + rituximab (2 arms). Primary endpoints: Recommended Phase 3 Dose of tazemetostat in combination with lenalidomide and rituximab, Progression-free survival in the intent-to-treat wild-type population and 3 more. Planned start Jan 2022; status: authorised.
02
Drugs
tazemetostat
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2024-510690-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510690-16-00.